Yong Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yong Liu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Rong Su
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China, 510150
3 shared publicationsJiaming Wang
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China, 510150
2 shared publications- Yi Tang
Department of Breast Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
2 shared publications - Bei Jin
State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
1 shared publication Chunfu Li
Nanfang‐Chunfu Children's Institute of Hematology & Oncology TaiXin Hospital Dongguan China
1 shared publicationChunping Wu
Fujian Provincial Key Laboratory on Hematology, Department of Paeditric Hematology, Fujian Institute of Hematology Fujian Medical University Union Hospital Fuzhou China
1 shared publication
Latest Publications
- Open Access
- 17 May 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71879
Integrated Molecular Risk Stratification and Measurable Residual Disease‐Guided Consolidation Improve Outcomes in Pediatric Non‐Down Syndrome Acute Megakaryoblastic Leukemia
Management of pediatric acute megakaryoblastic leukemia (AMKL) without Down syndrome (non‐DS‐AMKL) remains challenging due to suboptimal induction responses and poor survival. This study assessed the efficacy of fludarabine, cytarabine, granulocyte colony‐stimulating factor, and idarubicin (FLAG‐IDA) in non‐DS‐AMKL and evaluated the role of risk‐adapted consolidation strategies, including hematopoietic stem cell transplantation (HSCT) during first complete remission (CR1), guided by genetic profiles and measurable residual disease (MRD) dynamics. In this multicenter retrospective study from China, we analyzed 58 non‐DS‐AMKL patients treated with FLAG‐IDA ( n = 50) or daunorubicin, cytarabine, etoposide (DAE) ( n = 8) induction, followed by risk‐adapted consolidation. FLAG‐IDA demonstrated CR rates comparable to those with DAE (first‐course: 70.0% vs. 87.5%, p = 0.423; cumulative: 82.0% vs. 87.5%, p = 1.000). Compared with other AML subtypes, non‐DS‐AMKL showed inferior 5‐year overall survival (OS) (61.7% vs. 78.2%, p = 0.001) and event‐free survival (EFS) (58.5% vs. 68.8%, p = 0.045), attributable to a higher relapse rate (34.8% vs. 19.5%, p = 0.002). High‐risk genetics predicted worse outcomes. HSCT in CR1 significantly improved survival for high‐risk or poor responders. CR with MRD negativity after second induction predicted superior OS and EFS ( p < 0.001). Risk‐adapted HSCT and MRD‐guided stratification are critical for non‐DS‐AMKL management.
- 17 May 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71879
Open AccessIntegrated Molecular Risk Stratification and Measurable Residual Disease‐Guided Consolidation Improve Outcomes in Pediatric Non‐Down Syndrome Acute Megakaryoblastic Leukemia
Management of pediatric acute megakaryoblastic leukemia (AMKL) without Down syndrome (non‐DS‐AMKL) remains challenging due to suboptimal induction responses and poor survival. This study assessed the efficacy of fludarabine, cytarabine, granulocyte colony‐stimulating factor, and idarubicin (FLAG‐IDA) in non‐DS‐AMKL and evaluated the role of risk‐adapted consolidation strategies, including hematopoietic stem cell transplantation (HSCT) during first complete remission (CR1), guided by genetic profiles and measurable residual disease (MRD) dynamics. In this multicenter retrospective study from China, we analyzed 58 non‐DS‐AMKL patients treated with FLAG‐IDA ( n = 50) or daunorubicin, cytarabine, etoposide (DAE) ( n = 8) induction, followed by risk‐adapted consolidation. FLAG‐IDA demonstrated CR rates comparable to those with DAE (first‐course: 70.0% vs. 87.5%, p = 0.423; cumulative: 82.0% vs. 87.5%, p = 1.000). Compared with other AML subtypes, non‐DS‐AMKL showed inferior 5‐year overall survival (OS) (61.7% vs. 78.2%, p = 0.001) and event‐free survival (EFS) (58.5% vs. 68.8%, p = 0.045), attributable to a higher relapse rate (34.8% vs. 19.5%, p = 0.002). High‐risk genetics predicted worse outcomes. HSCT in CR1 significantly improved survival for high‐risk or poor responders. CR with MRD negativity after second induction predicted superior OS and EFS ( p < 0.001). Risk‐adapted HSCT and MRD‐guided stratification are critical for non‐DS‐AMKL management.
- 30 May 2024
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 45 (12) , 940-952
Antitumor activity of niclosamide-mediated oxidative stress against acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a heterogeneous clonal disease originated from B- or T-cell lymphoid precursor cells. ALL is often refractory or relapses after treatment. Novel treatments are anxiously needed in order to achieve a better response and prolonged overall survival in ALL patients. In the present study, we aimed at examining the anti-tumor effect of niclosamide on ALL. We investigated the effects of niclosamide on the proliferation and apoptosis in vitro, the growth of ALL cells in xenografted NCG mice. The results showed that niclosamide treatment potently inhibited the growth of ALL cells and induced apoptosis via elevating the levels of reactive oxygen species (ROS) and activating TP53. These findings suggest that niclosamide may be a promisingly potential agent for ALL therapy.
- 30 May 2024
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 45 (12) , 940-952
Antitumor activity of niclosamide-mediated oxidative stress against acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a heterogeneous clonal disease originated from B- or T-cell lymphoid precursor cells. ALL is often refractory or relapses after treatment. Novel treatments are anxiously needed in order to achieve a better response and prolonged overall survival in ALL patients. In the present study, we aimed at examining the anti-tumor effect of niclosamide on ALL. We investigated the effects of niclosamide on the proliferation and apoptosis in vitro, the growth of ALL cells in xenografted NCG mice. The results showed that niclosamide treatment potently inhibited the growth of ALL cells and induced apoptosis via elevating the levels of reactive oxygen species (ROS) and activating TP53. These findings suggest that niclosamide may be a promisingly potential agent for ALL therapy.
- Open Access
- 1 July 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 6053-6058
Surgical Management Strategy for Breast Cancer Patients During the COVID-19 Outbreak
In December 2019, a new coronavirus pneumonia began to break out globally. COVID-19 pandemic challenges the health systems worldwide and influences the treatments for other diseases. The incidence rate of breast cancer ranks first among all malignant tumors among women. During the pandemic, medical workers should strictly monitor the condition of patients and strengthen the management and prevention measures to make sure patients can be operated safely. This article will discuss the arrangements and management of surgical treatment for patients with breast cancer.
- 1 July 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 6053-6058
Open AccessSurgical Management Strategy for Breast Cancer Patients During the COVID-19 Outbreak
In December 2019, a new coronavirus pneumonia began to break out globally. COVID-19 pandemic challenges the health systems worldwide and influences the treatments for other diseases. The incidence rate of breast cancer ranks first among all malignant tumors among women. During the pandemic, medical workers should strictly monitor the condition of patients and strengthen the management and prevention measures to make sure patients can be operated safely. This article will discuss the arrangements and management of surgical treatment for patients with breast cancer.
- Open Access
- 11 January 2020
- Published by Springer Nature in Breast Cancer
- Vol. 27 (4) , 780-784
Postoperative radiotherapy-induced leiomyosarcoma in breast cancer: a case report and literature review
Radiation-induced sarcoma (RIS) is a late complication of breast cancer radiotherapy, with a very low incidence, long latent period and poor prognosis. Among them, leiomyosarcoma after radiation is an extremely rare radiation-associated sarcoma. In this study, we report a case of radiation-induced leiomyosarcoma 2 years after postoperative radiotherapy for breast cancer. After the diagnosis of leiomyosarcoma, the patient received radical resection of the left chest wall leiomyosarcoma. The patient showed no relapse or progression during the follow-up time of 1 year after operation. Rare occurrence of RIS induced by postoperative radiotherapy in breast cancer and limited experience concerning its diagnosis and treatment bring obstacle to both patients and doctors. Preoperative examinations must be carefully refined. With a perfect coordination between different disciplines, RIS induced by postoperative radiotherapy in breast cancer can be ideally treated with better prognosis.
- 11 January 2020
- Published by Springer Nature in Breast Cancer
- Vol. 27 (4) , 780-784
Open AccessPostoperative radiotherapy-induced leiomyosarcoma in breast cancer: a case report and literature review
Radiation-induced sarcoma (RIS) is a late complication of breast cancer radiotherapy, with a very low incidence, long latent period and poor prognosis. Among them, leiomyosarcoma after radiation is an extremely rare radiation-associated sarcoma. In this study, we report a case of radiation-induced leiomyosarcoma 2 years after postoperative radiotherapy for breast cancer. After the diagnosis of leiomyosarcoma, the patient received radical resection of the left chest wall leiomyosarcoma. The patient showed no relapse or progression during the follow-up time of 1 year after operation. Rare occurrence of RIS induced by postoperative radiotherapy in breast cancer and limited experience concerning its diagnosis and treatment bring obstacle to both patients and doctors. Preoperative examinations must be carefully refined. With a perfect coordination between different disciplines, RIS induced by postoperative radiotherapy in breast cancer can be ideally treated with better prognosis.
- 1 January 2019
- Vol. 12 (11) , 3982-3991
Serum microRNA-195 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis
Serum microRNA-195 (miR-195) expression has been shown to be significantly up-regulated in breast cancer, which implies that it could be a useful biomarker in the early detection of breast cancer. Hence, we performed this meta-analysis to investigate the diagnostic value of miR-195 for breast cancer. Relevant articles were collected from PubMed, Scopus, Embase, the Cochrane Library, BioMed Central, ISI Web of Knowledge, China National Knowledge Infrastructure, Wan Fang Data and Technology of Chongqing databases, from inception to May 24, 2019, by two independent researchers. The diagnostic capacity of miR-195 for breast cancer was assessed using pooled sensitivity and specificity, diagnostic odds ratio (DOR), area under the summary receiver operating characteristic (AUC) and Fagan's nomogram. Meta-analysis and heterogeneity source investigation were completed using Meta-Disc statistical software and Stata SE (version 14.0). Six studies with a total of 464 patients and 287 healthy controls were included in our meta-analysis. The pooled results for sensitivity, specificity and DOR were 0.79 (95% CI: 0.75-0.83), 0.86 (95% CI: 0.82-0.90) and 32.05 (95% CI: 17.04-60.30), respectively; positive and negative likelihood ratios were 5.18 and 0.20, and AUC was 0.9197 (95% CI: 0.86-0.91). In addition, heterogeneity was clearly apparent but was not caused by the threshold effect. In summary, this meta-analysis revealed that miR-195 may be suitable as a potential biomarker for early diagnosis of breast cancer with high sensitivity and specificity, and further investigations are needed to demonstrate its clinical application value.
- 1 January 2019
- Vol. 12 (11) , 3982-3991
Serum microRNA-195 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis
Serum microRNA-195 (miR-195) expression has been shown to be significantly up-regulated in breast cancer, which implies that it could be a useful biomarker in the early detection of breast cancer. Hence, we performed this meta-analysis to investigate the diagnostic value of miR-195 for breast cancer. Relevant articles were collected from PubMed, Scopus, Embase, the Cochrane Library, BioMed Central, ISI Web of Knowledge, China National Knowledge Infrastructure, Wan Fang Data and Technology of Chongqing databases, from inception to May 24, 2019, by two independent researchers. The diagnostic capacity of miR-195 for breast cancer was assessed using pooled sensitivity and specificity, diagnostic odds ratio (DOR), area under the summary receiver operating characteristic (AUC) and Fagan's nomogram. Meta-analysis and heterogeneity source investigation were completed using Meta-Disc statistical software and Stata SE (version 14.0). Six studies with a total of 464 patients and 287 healthy controls were included in our meta-analysis. The pooled results for sensitivity, specificity and DOR were 0.79 (95% CI: 0.75-0.83), 0.86 (95% CI: 0.82-0.90) and 32.05 (95% CI: 17.04-60.30), respectively; positive and negative likelihood ratios were 5.18 and 0.20, and AUC was 0.9197 (95% CI: 0.86-0.91). In addition, heterogeneity was clearly apparent but was not caused by the threshold effect. In summary, this meta-analysis revealed that miR-195 may be suitable as a potential biomarker for early diagnosis of breast cancer with high sensitivity and specificity, and further investigations are needed to demonstrate its clinical application value.